Advances in Hematology and Oncology Research(AHOR)
ISSN: 2692-5516 | DOI: 10.33140/AHOR
Impact Factor: 1.25*
Researchers and authors can directly submit their manuscript online through this link Online Manuscript Submission.
Outcomes of Brentuximab Vedotin with or without Bendamustine and Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma: An Early Experience from Patient Access Programme in India
Citation
Jyothi Goutham, Samrudhi Joshi, Shekar Patil, Satheesh Chiradoni Thungappa, Ravi Thippeswamy, Shashidha-ra HP, Nishit Ojha, Amey C Panchal, Yesheswini N Naik, Jayantha Balawardane and Sachin Suresh Jadhav
Goutham, J., Joshi, S., Patil, S., Thungappa, S. C., Thippeswamy, R., et al. (2024). Outcomes of Brentuximab Vedotin with or without Bendamustine and Nivolumab in Relapsed or Refractory Hodgkin?s Lymphoma: An Early Experience from Patient Access Programme in India. Adv Hema Onco Res, 7(1), 01-07.